Empirical Finance LLC decreased its position in AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 5.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 3,813 shares of the company’s stock after selling 228 shares during the period. Empirical Finance LLC’s holdings in AstraZeneca were worth $222,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds have also recently modified their holdings of the company. OLD Mission Capital LLC purchased a new position in shares of AstraZeneca during the 3rd quarter valued at about $7,581,000. Venturi Wealth Management LLC raised its stake in shares of AstraZeneca by 4.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 21,689 shares of the company’s stock valued at $1,303,000 after buying an additional 996 shares during the last quarter. Stephens Inc. AR raised its stake in shares of AstraZeneca by 21.7% during the 3rd quarter. Stephens Inc. AR now owns 20,327 shares of the company’s stock valued at $1,221,000 after buying an additional 3,621 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in shares of AstraZeneca by 13.1% during the 3rd quarter. Commonwealth Equity Services LLC now owns 161,626 shares of the company’s stock valued at $9,707,000 after buying an additional 18,783 shares during the last quarter. Finally, Banque Cantonale Vaudoise increased its stake in shares of AstraZeneca by 21.9% in the 3rd quarter. Banque Cantonale Vaudoise now owns 1,548 shares of the company’s stock valued at $93,000 after purchasing an additional 278 shares in the last quarter. Institutional investors own 20.54% of the company’s stock.
Several equities analysts recently weighed in on the company. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating and set a $61.00 price target for the company in a research note on Tuesday, January 4th. Deutsche Bank Aktiengesellschaft lifted their price target on AstraZeneca from £105 ($136.61) to £115 ($149.62) in a research note on Wednesday, April 6th. Credit Suisse Group lifted their price target on AstraZeneca from GBX 9,000 ($117.10) to £110 ($143.12) in a research note on Friday, April 8th. Stifel Nicolaus assumed coverage on AstraZeneca in a research note on Monday, February 28th. They issued a “buy” rating for the company. Finally, JPMorgan Chase & Co. lifted their price target on AstraZeneca from £100 ($130.11) to £120 ($156.13) in a research note on Thursday, April 7th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $6,669.29.
AstraZeneca (NASDAQ:AZN – Get Rating) last issued its earnings results on Thursday, February 10th. The company reported $0.84 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.07. The business had revenue of $11.50 billion for the quarter, compared to analysts’ expectations of $11.06 billion. AstraZeneca had a return on equity of 27.48% and a net margin of 0.30%. The business’s revenue for the quarter was up 55.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.54 EPS. As a group, equities analysts forecast that AstraZeneca PLC will post 3.31 EPS for the current fiscal year.
The business also recently announced a semi-annual dividend, which was paid on Monday, March 28th. Stockholders of record on Friday, February 25th were issued a dividend of $0.985 per share. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.45. This represents a dividend yield of 2.4%. The ex-dividend date was Thursday, February 24th. AstraZeneca’s payout ratio is currently 1,378.67%.
AstraZeneca Company Profile (Get Rating)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- 3 No-Brainer Stocks to Buy with $1000
- Rite Aid Stock is Getting Cheap Enough to Buy Here
- Analysts Reel In Netflix Targets Ahead Of Q1 Earnings
- MarketBeat Podcast: Making Money in the Red-Hot Housing Market
- Banking On Bank Of America
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.